TG Therapeutics, Inc. (TGTX) is a publicly traded Healthcare sector company. As of August 24, 2026, TGTX trades at $55.25 with a market cap of $8.31B and a P/E ratio of 17.82. TGTX moved +7.32% today. Year to date, TGTX is +82.05%; over the trailing twelve months it is +88.63%. Its 52-week range spans $25.28 to $59.30. Analyst consensus is buy with an average price target of $65.14. Rallies surfaces TGTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks TGTX insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $55.25 |
| Market Cap | $8.31B |
| P/E Ratio | 17.82 |
| EPS | $3.10 |
| Dividend Yield | 0.00% |
| 52-Week High | $59.30 |
| 52-Week Low | $25.28 |
| Volume | 5.00M |
| Avg Volume | 0 |
| Revenue (TTM) | $616.29M |
| Net Income | $447.18M |
| Gross Margin | 83.66% |
7 analysts cover TGTX: 0 strong buy, 5 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $65.14.